201 related articles for article (PubMed ID: 32580619)
1. Activity of Omadacycline and Other Tetracyclines Against Contemporary Gram-Negative Pathogens from New York City Hospitals.
Iregui A; Landman D; Quale J
Microb Drug Resist; 2021 Feb; 27(2):190-195. PubMed ID: 32580619
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.
Pfaller MA; Huband MD; Rhomberg PR; Flamm RK
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223386
[TBL] [Abstract][Full Text] [Related]
3. Comparative
Mirza HC; Güçlü AÜ; İnce Ceviz G; Başustaoğlu A
J Med Microbiol; 2022 Oct; 71(10):. PubMed ID: 36301611
[No Abstract] [Full Text] [Related]
4. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Quale J; Landman D
Antimicrob Agents Chemother; 2015 Aug; 59(8):4856-60. PubMed ID: 26033723
[TBL] [Abstract][Full Text] [Related]
5. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.
Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J
Antimicrob Agents Chemother; 2015 Mar; 59(3):1802-5. PubMed ID: 25534744
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.
Pfaller MA; Huband MD; Shortridge D; Flamm RK
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071045
[TBL] [Abstract][Full Text] [Related]
9. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018.
Dong D; Zheng Y; Chen Q; Guo Y; Yang Y; Wu S; Zhu D; Deng D; Bradford PA; Reinhart H; Hu F
Eur J Clin Microbiol Infect Dis; 2020 Aug; 39(8):1559-1572. PubMed ID: 32356026
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).
Carvalhaes CG; Huband MD; Reinhart HH; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617092
[TBL] [Abstract][Full Text] [Related]
12. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
14. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).
Pfaller MA; Rhomberg PR; Huband MD; Flamm RK
Diagn Microbiol Infect Dis; 2018 Jun; 91(2):179-183. PubMed ID: 29571839
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.
Xiao M; Huang JJ; Zhang G; Yang WH; Kong F; Kudinha T; Xu YC
BMC Microbiol; 2020 Nov; 20(1):350. PubMed ID: 33198626
[TBL] [Abstract][Full Text] [Related]
17. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
Macone AB; Caruso BK; Leahy RG; Donatelli J; Weir S; Draper MP; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(2):1127-35. PubMed ID: 24295985
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of colistin-resistant, carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Croatia.
D'Onofrio V; Conzemius R; Varda-Brkić D; Bogdan M; Grisold A; Gyssens IC; Bedenić B; Barišić I
Infect Genet Evol; 2020 Jul; 81():104263. PubMed ID: 32105865
[TBL] [Abstract][Full Text] [Related]
20. Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City.
Iregui A; Khan Z; Landman D; Quale J
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
